|
New relevant references have been identified through a structured assessment of the literature and incorporated in the various chapters of the 2021 EAU MIBC Guidelines resulting in new sections and added and revised recommendations in: 通过对文献进行结构化评估，确定了新的相关参考文献，并将其纳入《2021年EAU MIBC指南》的各个章节中，所以，新增了以下章节和建议，也修改了部分建议： Section 3.3.3 Guidelines for the assessment of tumour specimens 第3.3.3节 肿瘤标本的评估指南 Section 5.1.8 Summary of evidence and guidelines for the primary assessment of presumably invasive bladder tumours 第5.1.8节 推测为浸润性膀胱肿瘤的初步评估证据概述和指南 Section 5.2.1 – Local staging of MIBC; inclusion of data on multiparametric MRI using the Vesical Imaging Reporting and Data System (VI-RADS) scoring system. No new recommendation has been provided. 第5.2.1节– MIBC的术前分期；包括使用血管成像报告和数据系统（VI-RADS）评分系统进行多参数MRI。没有提供新的建议。 Section 5.3 – MIBC and health status; this section has been updated, introducing the concept of frailty. 第5.3节—MIBC和健康状况；本节已更新，介绍了frailty（衰弱，虚弱）的概念。 Chapter 6 – Markers; this chapter has been significantly revised, presenting two new recommendations. 第6章—标志物；本章进行了大幅修订，新提出了两条建议。 6.5 Summary of evidence and recommendations for urothelial markers 6.5尿路上皮癌标志物的证据概述和建议 Section 7.2 – Pre- and post-operative radiotherapy in muscle-invasive bladder cancer; this section was revised and new data added, resulting in an additional recommendation. 第7.2节–肌层浸润性膀胱癌的术前和术后放疗；本节进行了修订，并添加了新数据，增加了一条建议。 7.2.3 Summary of evidence and guidelines for pre- and post-operative radiotherapy 7.2.3术前和术后放疗的证据概述和指南 7.3.10 Summary of evidence and guidelines for radical cystectomy and urinary diversion 7.3.10根治性膀胱切除术和尿流改道的证据概述和指南 7.5.4 Trimodality bladder-preserving treatment 第7.5.4节 保留膀胱的三联疗法 7.7 Metastatic disease: data from a number of key trials has been included, in particular on immunotherapy combinations in first- and later-line setting, resulting in a number of new recommendations and a change to the treatment flowchart (Figure 7.2). 第7.7节 转移性疾病：纳入了许多关键试验的数据，特别是一线和随后治疗的免疫联合疗法数据，新增了许多建议，修改了治疗流程图（图7.2）。 7.7.8 Summary of evidence and guidelines for metastatic disease 7.7.8转移性疾病的证据概述和指南 GC = gemcitabine plus cisplatin吉西他滨加顺铂 FGFR = fibroblast growth factor receptor成纤维细胞生长因子受体 HD-MVAC = high-dose intensity methotrexate, vinblastine, adriamycin plus cisplatin 高剂量甲氨蝶呤、长春碱、阿霉素加顺铂 声明： 本文来自柳叶新潮内容团队 |
|
|
